H

Halozyme Therapeutics, Inc.

450 employees

Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
hyaluronidase
biotechnology
Medical
rHuPH20
subcutaneous biologics
Marketing

Date founded

1998

Funding rounds raised

Total raised

$150M

from 5 investors over 5 rounds

H

Halozyme Therapeutics, Inc. raised $30M on February 6, 2019

Investors: argenx

H

Halozyme Therapeutics, Inc. raised $150M on January 5, 2016

Investors: Pharmakon Advisors, LP and Athyrium Capital Management, LP

H

Halozyme Therapeutics, Inc. raised $20M on January 6, 2014

Investors: Oxford Finance LLC

H

Halozyme Therapeutics, Inc. raised $30M on December 27, 2013

Investors: Oxford Finance LLC

FAQ